Schisandrin B: A dual inhibitor of P-glycoprotein and multidrug resistance-associated protein 1

Cancer Letters

Volumn 246, Issue 1-2, 2007, Pages 300-307

  Sun, Meng ^a   Xu, Xiaoli ^a   Lu, Qinghua ^a   Pan, Qiangrong ^a   Hu, Xun ^a  

^a THE SECOND AFFILIATED HOSPITAL OF ZHEJIANG UNIVERSITY SCHOOL OF MEDICINE   (China)

Author keywords

Cancer multidrug resistance; Multidrug resistance associated protein 1; Probenecid; Schisandrin B

Indexed keywords

BENZENE DERIVATIVE; CARBOXYFLUORESCEIN; CARBOXYFLUORESCEIN DIACETATE; DAUNORUBICIN; ETOPOSIDE; GLYCOPROTEIN P; GLYCOPROTEIN P INHIBITOR; MITOXANTRONE; MULTIDRUG RESISTANCE PROTEIN 1; PACLITAXEL; PROBENECID; PROTEIN INHIBITOR; SCHISANDRIN B; VINCRISTINE;

ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER RESISTANCE; CELL STRAIN HL 60; CONTROLLED STUDY; DOSE TIME EFFECT RELATION; DRUG ACCUMULATION; DRUG POTENCY; DRUG RETENTION; DRUG SENSITIVITY; GENE OVEREXPRESSION; HUMAN; HUMAN CELL; MULTIDRUG RESISTANCE; PRIORITY JOURNAL; PROMYELOCYTIC LEUKEMIA;

ANTIBIOTICS, ANTINEOPLASTIC; CYCLOOCTANES; DAUNORUBICIN; DOSE-RESPONSE RELATIONSHIP, DRUG; DOXORUBICIN; DRUG RESISTANCE, MULTIPLE; DRUG RESISTANCE, NEOPLASM; FLOW CYTOMETRY; FLUORESCEINS; GENE EXPRESSION REGULATION, NEOPLASTIC; HL-60 CELLS; HUMANS; LIGNANS; MOLECULAR STRUCTURE; MULTIDRUG RESISTANCE-ASSOCIATED PROTEINS; P-GLYCOPROTEIN; POLYCYCLIC COMPOUNDS; PROBENECID; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER;

EID: 33845643674     PISSN: 03043835     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.canlet.2006.03.009     Document Type: Article

References (39)

1. Gottesman M.M., Tito F., and Bates S.E. Multidrug resistance in cancer: role of ATP-dependent transporters. Nat. Rev. Cancer 1 (2002) 48-58
2. Schinkel A.H., and Jonker J.W. Mammalian drug efflux transporters of the ATP binding cassette (ABC) family: an overview. Adv. Drug Deliv. Rev. 55 (2003) 3-29
3. Hipfner D.R., Deeley R.G., and Cole S.P. Structural, mechanistic and clinical aspects of MRP1. Biochim. Biophys. Acta 1461 (1999) 359-376
4. Cole S.P.C., and Deeley R.G. Multidrug resistance associated with overexpression of MRP. In: Hait W.N. (Ed). Drug Resistance (1996), Kluwer Academic Press, Norwell, MA 39-62 (Chapter 2)
5. Loe D.W., Deeley R.G., and Cole S.P.C. Biology of drug resistance associated with overexpression of the multidrug resistance protein, MRP. Eur. J. Cancer 32 (1996) 945-957
6. Campling B.G., Young L.C., Baer K.A., Lam Y.-M., Deeley R.G., Cole S.P.C., and Gerlach J.H. Expression of the MRP and MDR1 multidrug resistance genes in small cell lung cancer. Clin. Cancer Res. 3 (1997) 115-122
7. Wright S.R., Boag A.H., Valdimarsson G., Hipfner D.R., Campling B.G., Cole S.P., and Deeley R.G. Immunohistochemical detection of multidrug resistance protein in human lung cancer and normal lung. Clin. Cancer Res. 9 (1998) 2279-2289
8. Filipits M., Suchomel R.W., Dekan G., Stiglbauer W., Haider K., Depisch D., and Pirker R. Expression of the multidrug resistance-associated protein (MRP) gene in colorectal carcinomas. Br. J. Cancer 75 (1997) 208-212
9. Endo K., Maehara Y., Ichiyoshi Y., Kusumoto T., Sakaguchi Y., Ohno S., and Sugimachi K. Multidrug resistance-associated protein expression in clinical gastric carcinoma. Cancer 77 (1996) 1681-1687
10. Takebayashi Y., Akiyama S., Natsugoe S., Hokita S., Niwa K., Kitazono M., et al. The expression of multidrug resistance protein in human gastrointestinal tract carcinomas. Cancer 82 (1998) 661-666
11. Nooter K., Kok T., Bosman F.T., van Wingerden K.E., and Stoter G. Expression of the multidrug resistance protein (MRP) in squamous cell carcinoma of the oesophagus and response to pre-operative chemotherapy. Eur. J. Cancer 34 (1998) 81-86
12. Chan H.S., Grogan T.M., Haddad G., Hipfner D.R., Deeley R.G., and Cole S.P. Standardization of a single-cell assay for sensitive detection of multidrug resistance protein expression in normal and malignant cells in archival clinical samples. J. Lab. Clin. Med. 130 (1997) 297-306
13. Chan H.S., Lu Y., Grogan T.M., Haddad G., Hipfner D.R., Cole S.P., et al. Multidrug resistance protein (MRP) expression in retinoblastoma correlates with the rare failure of chemotherapy despite cyclosporine for reversal of P-glycoprotein. Cancer Res. 57 (1997) 2325-2330
14. Nooter K., de la Riviere G.B., Klijn J., Stoter G., and Foekens J. Multidrug resistance protein in recurrent breast cancer. Lancet 349 (1997) 1885-1886
15. Linn S.C., Pinedo H.M., van Ark-Otte J., van der Valk P., Hoekman K., and Honkoop A.H. Expression of drug resistance proteins in breast cancer, in relation to chemotherapy. Int. J. Cancer 71 (1997) 787-795
16. Sullivan G.F., Amenta P.S., Villanueva J.D., Alvarez C.J., Yang J.M., and Hait W.N. The expression of drug resistance gene products during the progression of human prostate cancer. Clin. Cancer Res. 4 (1998) 1393-1403
17. Abe T., Mori T., Wakabayashi Y., Nakagawa M., Cole S.P., Koike K., et al. Expression of multidrug resistance protein gene in patients with glioma after chemotherapy. J. Neurooncol. 40 (1998) 11-18
18. Filipits M., Suchomel R.W., Zochbauer S., Brunner R., Lechner K., and Pirker R. Multidrug resistance-associated protein in acute myeloid leukemia: no impact on treatment outcome. Clin. Cancer Res. 3 (1997) 1419-1425
19. Filipits M., Suchomel R.W., Lechner K., and Pirker R. Immunocytochemical detection of the multidrug resistance-associated protein and P-glycoprotein in acute myeloid leukemia: impact of antibodies, sample source and disease status. Leukemia 11 (1997) 1073-1077
20. Zhan Z., Sandor V.A., Gamelin E., Regis J., Dickstein B., Wilson W., et al. Expression of the multidrug resistance-associated protein gene in refractory lymphoma: quantitation by a validated polymerase chain reaction assay. Blood 89 (1997) 3795-3800
21. den Boer M.L., Pieters R., Kazemier K.M., Rottier M.M., Zwaan C.M., Kaspers G.J., et al. Relationship between major vault protein/lung resistance protein, multidrug resistance-associated protein, P-glycoprotein expression, and drug resistance in childhood leukemia. Blood 91 (1998) 2092-2098
22. Stewart A.J., Canitrot Y., Baracchini E., Dean N.M., Deeley R.G., and Cole S.P. Reduction of expression of the multidrug resistance protein (MRP) in human tumor cells by antisense phosphorothioate oligonucleotides. Biochem. Pharmacol. 51 (1996) 461-469
23. Le Beau M.M., Larson R.A., Bitter M.A., Vardiman J.W., Golomb H.M., and Rowley J.D. Association of an inversion of chromosome 16 with abnormal marrow eosinophils in acute myelomonocytic leukemia. A unique cytogenetic-clinicopathological association. N. Engl. J. Med. 309 (1983) 630-636
24. Minderman H., O'Loughlin K.L., Pendyala L., and Baer M.R. VX-710 (biricodar) increases drug retention and enhances chemosensitivity in resistant cells overexpressing P-glycoprotein, multidrug resistance protein, and breast cancer resistance protein. Clin. Cancer Res. 10 (2004) 1826-1834
25. Narasaki F., Oka M., Fukuda M., Nakano R., Ikeda K., and Takatani H. A novel quinoline derivative, MS-209, overcomes drug resistance of human lung cancer cells expressing the multidrug resistance-associated protein (MRP) gene. Cancer Chemother. Pharmacol. 40 (1997) 425-432
26. Robert J., and Jarry C. Multidrug resistance reversal agents. J. Med. Chem. 46 (2003) 4805-4817
27. Ip S.P., Poon M.K., Wu S.S., Che C.T., Ng K.H., Kong Y.C., and Ko K.M. Effect of schisandrin B on hepatic glutathione antioxidant system in mice: protection against carbon tetrachloride toxicity. Planta Med. 61 (1995) 398-401
28. Chiu P.Y., and Ko K.M. Schisandrin B protects myocardial ischemia-reperfusion injury partly by inducing Hsp25 and Hsp70 expression in rats. Mol. Cell. Biochem. 266 (2004) 139-144
29. Ko K.M., and Lam B.Y. Schisandrin B protects against tertbutylhydroperoxide induced cerebral toxicity by enhancing glutathione antioxidant status in mouse brain. Mol. Cell. Biochem. 238 (2002) 181-186
30. Pan Q., Wang T., Lu Q., and Hu X. Schisandrin B-A novel inhibitor of P-glycoprotein. Biochem. Biophys. Res. Commun. 335 (2005) 406-411
31. Q. Pan, Q. Lu, K. Zhang, X. Hu. Dibenzocyclooctadiene-a class of novel inhibitors of P-glycoproteins, Cancer Chemother. Pharmacol., 2005 (E-pub ahead of print).
32. L. Li, Q. Lu, X. Hu, Schisandrin B enhances doxorubicin-induced apoptosis of cancer cells but not normal cells, Biochem. Pharmcol. 71 (2006) 584-595.
33. Dogan A.L., Legrand O., Faussat A.M., Perrot J.Y., and Marie J.P. Evaluation and comparison of MRP1 activity with three fluorescent dyes and three modulators in leukemic cell lines. Leukaemia Res. 28 (2004) 619-622
34. Gollapudi S., Kim C.H., Tran B.N., Sangha S., and Gupta S. Probenecid reverses multidrug resistance in multidrug resistance-associated protein-overexpressing HL60/AR and H69/AR cells but not in P-glycoprotein-overexpressing HL60/Tax and P388/ADR cells. Cancer Chemother. Pharmacol. 40 (1997) 150-158
35. Minderman H., Brooks T.A., O'Loughlin K.L., Ojima I., Bernacki R.J., and Baer M.R. Broad-spectrum modulation of ATP-binding cassette transport proteins by the taxane derivatives ortataxel (IDN-5109, BAY 59-8862) and tRA96023. Cancer Chemother. Pharmacol. 53 (2004) 363-369
36. Boumendjel A., Baubichon-Cortay H., Trompier D., Perrotton T., and Di Pietro A. Anticancer multidrug resistance mediated by MRP1: recent advances in the discovery of reversal agents. Med. Res. Rev. 25 (2005) 453-472
37. Ip S.P., and Ko K.M. The crucial antioxidant action of Sch B in protecting against carbon tetrachloride hepatotoxicity in mice: a comparative study with butylated hydroxytoluene. Biochem. Pharmacol. 52 (1996) 1687-1693
38. Ip S.P., and Ko K.M. The crucial antioxidant action of Sch B in protecting against carbon tetrachloride hepatotoxicity in mice: a comparative study with butylated hydroxytoluene. Biochem. Pharmacol. 52 (1996) 1687-1693
39. Hanck J.L., Burgos R.A., and Ahumanda F. Schisandra chinensis(Turcz.) Bail. Fitoterapia 70 (1999) 451-471